Loading company…
Novus Therapeutics develops therapies intended to improve organ transplant outcomes.
Novus Therapeutics develops tegoprubart, an anti-CD40L antibody being studied to reduce organ rejection, including in kidney transplant patients. The company is also exploring potential use in liver transplantation and xenotransplantation. Formed in 2017 through the merger of Tokai Pharmaceuticals Inc. and Otic Pharma Ltd., it is based in Irvine, US. David-Alexandre Gros is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in